120 related articles for article (PubMed ID: 6485956)
21. [Quantitative measurement and clinical analysis of serum levels of immunosuppressive acidic protein (IAP) in hematopoietic malignancies].
Hamaguchi H; Karitani Y; Minami N; Tanaka I; Iwata Y; Shirakawa S
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1231-6. PubMed ID: 6732251
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of measurement of immunosuppressive acidic protein (IAP) in lung cancer].
Kondo H; Seno N; Matsuo S; Otagaki S; Matsuki T; Hatayama T
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2163-70. PubMed ID: 6625623
[TBL] [Abstract][Full Text] [Related]
24. [Clinical evaluation of a serum immunosuppressive (IS) substance in various diseases].
Mannami T; Fuchimoto S; Amamiya S; Morioka S; Tanaka S; Tanaka N; Konaga E; Orita K
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2104-12. PubMed ID: 6191693
[TBL] [Abstract][Full Text] [Related]
25. Induction of impaired activation of lymphocytes by suppressive factor in Crohn's disease patients.
Watanabe M; Tsuru S; Aiso S; Hibi T; Yoshida T; Asakura H; Zinnaka Y; Tsuchiya M
J Clin Lab Immunol; 1984 May; 14(1):29-34. PubMed ID: 6748044
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of immunosuppressive acid protein (IAP) in patients with rheumatoid arthritis].
Ueyoshi A; Ota K
Ryumachi; 1992 Apr; 32(2):131-4. PubMed ID: 1595004
[TBL] [Abstract][Full Text] [Related]
27. [Clinical use of the serum level of immuno-suppressive acidic protein (IAP) in gastroenterological surgery].
Tada I; Okuma T; Hongo H; Sada E; Tashiro S; Miyauchi Y
Gan No Rinsho; 1983 Apr; 29(4):A-20, 315-20. PubMed ID: 6854966
[TBL] [Abstract][Full Text] [Related]
28. Serum level of immunosuppressive acidic protein in patients with urological malignancies.
Pu YS; Tsai TC; Chiu TY; Hsieh TS; Chen J; Chen SC; Lin MC; Hsu TC
J Formos Med Assoc; 1991 May; 90(5):498-503. PubMed ID: 1680990
[TBL] [Abstract][Full Text] [Related]
29. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
[TBL] [Abstract][Full Text] [Related]
30. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Casella R; Shariat SF; Monoski MA; Lerner SP
Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
[TBL] [Abstract][Full Text] [Related]
31. [Studies on the cellular immune response in patients with urinary bladder carcinoma. XI: Evaluation of specific ADCC activity].
Nishio S; Asakawa M; Tanaka S; Wada S; Maekawa M; Kawamura M
Hinyokika Kiyo; 1986 May; 32(5):713-20. PubMed ID: 3751798
[TBL] [Abstract][Full Text] [Related]
32. [Variations in the level of immunosuppressive acidic protein in patients with gynecologic tumors and pregnant women].
Sawada M; Okudaira Y; Matsui Y; Miyoshi Y; Takayama K; Shimizu Y; Miura S
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1823-30. PubMed ID: 6882005
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer.
Battaglia F; Scambia G; Panici PB; Castelli M; Ferrandina G; Foti E; Amoroso M; D'Andrea G; Mancuso S
Gynecol Oncol; 1994 May; 53(2):176-82. PubMed ID: 8188076
[TBL] [Abstract][Full Text] [Related]
34. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
Wen R; Xie S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
[TBL] [Abstract][Full Text] [Related]
35. [Level and significance of the soluble interleukin-2 receptor expression in serum of patients with bladder cancer].
Wen R; Xie S; Ma P
Zhonghua Wai Ke Za Zhi; 1996 Jan; 34(1):16-8. PubMed ID: 9275680
[TBL] [Abstract][Full Text] [Related]
36. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival.
Munemoto Y; Iida Y; Abe J; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Int J Oncol; 2002 Feb; 20(2):403-11. PubMed ID: 11788909
[TBL] [Abstract][Full Text] [Related]
37. Studies on nonspecific cellular immune response in patients with urinary bladder carcinoma.
Nishio S; Morikawa Y; Horii A; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
Osaka City Med J; 1978; 24(1):51-71. PubMed ID: 752146
[No Abstract] [Full Text] [Related]
38. [Serum factors present in patients with carcinoma of the bladder: effect on cell-mediated immunity].
de la Fuente M; Aranda E; Molina I; Sánchez Guijo P; Peña J
Rev Esp Oncol; 1984; 31(2):257-64. PubMed ID: 6336253
[TBL] [Abstract][Full Text] [Related]
39. Immunosuppressive acidic protein (IAP) level in serum and peritoneal washings, and its implication in determining multidisciplinary treatments.
Takenoshita S; Tsukada K; Nakamura J; Shitara Y; Asao T; Kato R; Kojima T; Nagashima M; Nagamachi Y
Anticancer Res; 1996; 16(4B):2269-72. PubMed ID: 8694554
[TBL] [Abstract][Full Text] [Related]
40. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
